Appropriate Medication Selection
Choosing the right medicine is crucial for managing a minor neurocognitive problem in an 82-year-old male patient to guarantee safety and effectiveness. Memantine is the best option, given the patient’s age and condition, because of its unique ability to address the cognitive symptoms linked to neurodegenerative illnesses. Memantine reduces excessive glutamate activity, which can lead to dementia, by altering glutamatergic neurotransmission (Drugs, 2024a). It is imperative to manage older patients with this mode of action since it stabilizes cognitive functioning without having the significant sedative effects that other drugs may cause (Drugs, 2024a). In an elderly population, this focused therapy strategy substantially benefits cognitive function.
In this case, the hazards associated with the other options—lorazepam and olanzapine—outweigh the advantages. Despite being widely prescribed for its calming properties, lorazepam carries a considerable risk of worsening cognitive decline and making older patients drowsier (Drugs, 2023). It is inappropriate for a patient who is already suffering cognitive loss because of these adverse effects, which might increase the risk of falls and seriously impair mental alertness (Liu et al., 2020). In a similar vein, olanzapine’s risk profile includes metabolic disruptions and strong anticholinergic effects that could exacerbate cognitive symptoms and cause a patient with dementia-related disorders to decrease overall (Drugs, 2024b). Since olanzapine may interfere with metabolic processes, dosing for older people can be complicated and requires careful management of comorbidities.
Based on these factors, memantine reduces the risk of adverse effects, which is vital when caring for senior patients, while offering a focused approach to treating symptoms of moderate neurocognitive disease. As the reviewed literature highlights, memantine is preferred over other possible options because it avoids drugs with strong sedative and anticholinergic properties. This ensures that the treatment pathway aligns with best practices for this vulnerable population (BarĂ© et al., 2022). To improve the patient’s quality of life and level of independence, selecting memantine supports a deliberate focus on cognitive preservation and minimizing side effects.
Dosing Schedule and Therapeutic Endpoint
Memantine is to be started cautiously at 5 mg once daily and titrated progressively to a maintenance dose of 20 mg per day, divided into two doses of 10 mg each (Drugs, 2024a). This gradually modified dosage enables close monitoring of the patient’s response and subsequent adjustments as needed, reducing potential adverse effects and improving tolerance. Stabilizing the patient’s cognitive symptoms is the primary therapeutic aim of this course of treatment, with the ultimate goal of halting the trajectory of cognitive decline. This cautious dosing approach improves overall management of moderate neurocognitive impairments in older adults by ensuring that the medication delivers its targeted cognitive benefits while reducing the risk of adverse effects (Lau et al., 2020). As the patient’s condition changes, regular reassessment will be necessary to fine-tune the regimen to support the patient better.
Patient Education and Side Effects
Effective treatment management requires educating the patient and their caregivers about memantine’s benefits and potential adverse effects. Dizziness, disorientation, and headaches are among the side effects of memantine, which is used to treat the symptoms of neurocognitive disorders (Drugs, 2024a). Healthcare professionals should communicate the potential unfavorable effects on patients and their caregivers (Maidment et al., 2020). Their ability to recognize problems early improves safety and treatment compliance.
Patients should also be taught the correct dosing schedule and the importance of adhering to the recommended dosage without consulting their physician. Achieving the most excellent potential therapeutic outcomes requires adherence, reinforced by practical patient education that helps minimize treatment-related hazards (Maidment et al., 2020). The care plan should be kept up to date and functional by providing regular updates on new research or modifications to recommendations.
Necessary Labs and Diagnostics
A thorough diagnostic workup is necessary to establish a baseline and rule out alternative treatable causes of cognitive impairment before starting memantine treatment for neurocognitive disorders. Cognitive testing should be a part of the first examinations. Approved instruments, such as the Mini-Mental State Examination (MMSE), which provides a quantitative measure of cognitive status crucial for monitoring disease course and response to therapy, are recommended (Patnode et al., 2020).
Routine blood tests, in addition to cognitive examinations, are essential for screening for metabolic or endocrine problems that may mimic or worsen cognitive symptoms. Memantine’s renal excretion necessitates monitoring renal function to adjust doses and prevent toxicity, especially in older individuals whose kidney function may be impaired. Specific diagnostic techniques are necessary to ensure the safety and efficacy of memantine therapy and to tailor the treatment plan to the patient’s health profile.
Monitoring and Collaboration
Careful monitoring and teamwork are critical for managing a patient on memantine for cognitive deterioration. Routine follow-ups are vital for evaluating the medication’s effectiveness and monitoring for potential adverse effects. Cognitive functions should be routinely evaluated using standardized instruments to ascertain how the medicine impacts the patient’s cognitive status. Furthermore, because memantine is renally cleared, renal function tests are crucial for dosage adjustments that maximize therapeutic efficacy while minimizing risks (Lau et al., 2020).
Family members and home healthcare aides are integral to the patient’s everyday care and are also involved in collaboration outside the clinical context. It is paramount to inform these caregivers about memantine’s possible effects and side effects so they can efficiently help the patient. By working together, all stakeholders can be more coordinated in their efforts to deliver comprehensive care, thereby improving patient quality of life and overall treatment efficacy.
Addressing Non-Adherence
The ability of older individuals to independently manage their medication regimen must be thoroughly assessed to appropriately manage potential non-adherence in those patients who are prescribed memantine. Variables such as cognitive function, physical capacity, and the intricacy of the drug schedule can strongly impact adherence. Reminder systems and medication schedule simplification are two examples of strategies that can be helpful in this situation (Maidment et al., 2020). These metrics suggest that tailoring the routine and surroundings to the patient’s ability improves treatment compliance and efficacy.
Moreover, integrating home health aides or caregivers into daily medication management and using technological tools such as electronic drug dispensers can significantly increase adherence rates. These tools help maintain therapeutic drug levels in the patient’s system by assisting with the proper timing and dosage of medication administration. Turner (2022) asserts that appropriate prescription writing is essential to guarantee patient safety and improve the efficacy of the treatment plan.
According to Shah et al. (2023), alternative approaches such as routine telehealth follow-ups can be vital for assessing adherence and modifying the treatment plan to keep the patient informed and compliant. These all-encompassing approaches are crucial for addressing the complex issues of medication adherence in the senior population and enhancing quality of life and health outcomes.
References
Baré, M., Lleal, M., Ortonobes, S., Gorgas, M. Q., Sevilla-Sánchez, D., Carballo, N., De Jaime, E., & Herranz, S.(2022). Factors associated to potentially inappropriate prescribing in older patients according to STOPP/START criteria: MoPIM multicentre cohort study. BMC Geriatrics, 22(1), 44–56.
Drugs. (2023). Lorazepam prescribing information.
Drugs. (2024a). Memantine prescribing information.
Drugs. (2024b). Olanzapine tablets prescribing information.
Lau, S., Lun, P., Ang, W., Tan, K. T., & Ding, Y. Y. (2020). Barriers to effective prescribing in older adults: Applying the theoretical domains framework in the ambulatory setting – a scoping review. BMC Geriatrics, 20(1), 459–472.
Liu, L., Jia, L., Jian, P., Zhou, Y., Zhou, J., Wu, F., & Tang, Y. (2020). The effects of benzodiazepine use and abuse on cognition in the elders: A systematic review and meta-analysis of comparative studies. Frontiers in Psychiatry, 11, 1–11.
Maidment, I., Huckerby, C., & Shukla, D. (2020). Medication management in older people – A hidden burden. Prescriber, 31(11–12), 30–33.
Patnode, C. D., Perdue, L. A., Rossom, R. C., Rushkin, M. C., Redmond, N., Thomas, R., & Lin, J. S. (2020). Screening for cognitive impairment in older adults. JAMA, 323(8), 764–786.
Shah, A. Q., Noronha, N., Chin-See, R., Hanna, C., Kadri, Z., Marwaha, A., Rambharack, N., & Ng, J. Y. (2023). The use and effects of telemedicine on complementary, alternative, and integrative medicine practices: A scoping review. BMC Complementary Medicine and Therapies, 23(1), 1–40.
Turner, L. (2022). How to write a prescription: 7 steps for safety. Student Doctor Network.
